Prof. Dr. Se Hoon Lee
Cancer Treatment
About
Prof. Se Hoon Lee, M.D., Ph.D., is a Professor in the Division of Hematology-Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine at Seoul, South Korea. He received his degree from Seoul National University College of Medicine and is a highly esteemed surgeon worldwide, having published more than 300 papers and achieved an h-index of 50.
Professional Background
- Based In: Seoul, South Korea
- Experience: 20+ years
Innovations & Contributions
Prof. Lee's research is at the interface of molecular oncology and clinical translation, especially the prediction of response to immunotherapy.
- Genomic Predictors of Immunotherapy Response: Led the investigation of a DNA methylation loss signature and targeted sequencing data that are associated with the efficacy of immunotherapy (ICI) in lung cancer.
- Lung Adenocarcinoma: Co-authored landmark Genome Research study (2012) that provided a detailed characterization of the mutational and transcriptional profile of lung adenocarcinoma.
- ERBB2 Oncogenic Mutations: Provided functional analysis of extracellular domain ERBB2 mutations as lung cancer drivers, which was published in the PNAS.
- Clinical Trial Leadership: Principal Investigator for several international clinical trials such as KEYNOTE-181, for the further development of pembrolizumab in the treatment of advanced esophageal cancer.
Good to Know
Specialties
Languages Spoken
Awards
• International Association for the Study of Lung Cancer
• American Society of Clinical Oncology
• Korean Society of Medical Oncology
Professor of Medical Oncology
Samsung Medical Center
M.D., Ph.D.
Sungkyunkwan University School of Medicine
2005
Samsung Medical Center
Se Hoon Lee has been practicing medicine since 2005, giving them over 20 years of clinical experience. They currently serve as Professor, Division of Hematology-Oncology and have built a focused career in medical oncologist.
You can request a consultation with Se Hoon Lee through CureMeAbroad by submitting your details. Video consultations are available for international patients before travel through CureMeAbroad.
Cancer treatment costs with Se Hoon Lee vary by cancer type, stage, and treatment protocol. Patients frequently save 40-70% compared to equivalent care in the US or UK. CureMeAbroad can help obtain a cost estimate after your medical records and pathology reports are reviewed.
Se Hoon Lee practices at Samsung Medical Center specializing in lung cancer and thoracic oncology. The facility is equipped with modern surgical and diagnostic infrastructure, and maintains international accreditation standards to ensure a safe and reliable care environment for overseas patients.
Yes, Se Hoon Lee regularly treats patients from the US, UK, Europe, Australia, and the Middle East. Their hospital provides dedicated international patient support including pre-arrival medical record review, visa support letters, airport transfers, and coordination of post-travel follow-up care.
Se Hoon Lee specializes in oncology and treats a range of cancers using chemotherapy, targeted therapy, and immunotherapy protocols. Treatment plans are developed in coordination with a multidisciplinary tumor board to ensure a personalized, evidence-based approach for each patient.
How many years of experience does Se Hoon Lee have?
How can I book a consultation with Se Hoon Lee?
How much does treatment with Se Hoon Lee cost for international patients?
Which hospital or clinic does Se Hoon Lee practice at?
Does Se Hoon Lee treat international patients?
What types of cancer does Se Hoon Lee treat?
How many years of experience does Se Hoon Lee have?
Se Hoon Lee has been practicing medicine since 2005, giving them over 20 years of clinical experience. They currently serve as Professor, Division of Hematology-Oncology and have built a focused career in medical oncologist.
Which You Wanted To See
Help Me Plan
My
Treatment Abroad
Access exclusive hospital rates with zero service fees. Get an expert by your side for the entire journey—at no cost to you.
